Arrowhead Research Corp. (NASDAQ:ARWR) was downgraded by Piper Jaffray Cos. to a “neutral” rating in a research report issued on Wednesday.

Several other equities research analysts have also recently issued reports on the stock. Cantor Fitzgerald cut shares of Arrowhead Research Corp. to a “hold” rating in a research report on Wednesday. Chardan Capital cut shares of Arrowhead Research Corp. from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $8.00 to $2.00 in a research report on Wednesday. Jefferies Group decreased their target price on shares of Arrowhead Research Corp. from $6.50 to $5.00 and set a “hold” rating on the stock in a research report on Thursday, November 10th. Finally, William Blair began coverage on shares of Arrowhead Research Corp. in a research report on Friday, August 19th. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $8.81.

Analyst Recommendations for Arrowhead Research Corp. (NASDAQ:ARWR)

Arrowhead Research Corp. (NASDAQ:ARWR) opened at 4.39 on Wednesday. Arrowhead Research Corp. has a one year low of $3.07 and a one year high of $8.22. The firm’s market cap is $266.69 million. The stock has a 50 day moving average of $5.64 and a 200 day moving average of $6.10.

ILLEGAL ACTIVITY NOTICE: “Arrowhead Research Corp. (ARWR) Cut to Neutral at Piper Jaffray Cos.” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/30/arrowhead-research-corp-arwr-cut-to-neutral-at-piper-jaffray-cos.html.

In other Arrowhead Research Corp. news, Director Douglas B. Given sold 12,000 shares of Arrowhead Research Corp. stock in a transaction that occurred on Friday, October 14th. The shares were sold at an average price of $6.72, for a total transaction of $80,640.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of ARWR. RTW Investments LLC purchased a new stake in Arrowhead Research Corp. during the third quarter worth about $8,208,000. Credit Suisse AG raised its stake in Arrowhead Research Corp. by 8.9% in the third quarter. Credit Suisse AG now owns 161,640 shares of the company’s stock worth $1,190,000 after buying an additional 13,159 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in Arrowhead Research Corp. during the third quarter worth about $13,649,000. Highbridge Capital Management LLC purchased a new stake in Arrowhead Research Corp. during the third quarter worth about $275,000. Finally, Moors & Cabot Inc. raised its stake in Arrowhead Research Corp. by 11.0% in the third quarter. Moors & Cabot Inc. now owns 40,270 shares of the company’s stock worth $292,000 after buying an additional 4,000 shares in the last quarter. Institutional investors own 43.28% of the company’s stock.

Arrowhead Research Corp. Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

5 Day Chart for NASDAQ:ARWR

Receive News & Stock Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related stocks with our FREE daily email newsletter.